Persistent URL of this record https://hdl.handle.net/1887/3627440
Documents
-
- Download
- Full text
- Publisher's Version
- open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
Representativeness of phase III trial for osimertinib in pretreated advanced EGFR-mutated non-small-cell lung cancer patients and treatment outcomes in clinical practice
- All authors
- Lin, L.S.; Smit, E.F.; Langen, A.J. de; Balen, D.E.M. van; Beijnen, J.H.; Huitema, A.D.R.
- Date
- 2021-12-11
- Journal
- Targeted Oncology
- Volume
- 17
- Pages
- 53 - 59